The hottest Merck's annual performance hit a recor

  • Detail

Merck's annual performance hit a record high

Merck's annual performance hit a record high

March 13, 2015

[China paint information] the business was well operated. The acquisition of AZ electronic materials company boosted sales by 5.5%, and the EBITDA before one-time items increased by 4.1%, All reached the highest level in history

the four business branches achieved organic growth

emerging market businesses became the driving force of sales

Merck laid the foundation for future growth

reached the expected sales and EBITDA before one-time projects

Merck plans to increase its dividend by 5.3% to 1 euro per share

March 3, 2015, Germany 1 When using the concrete pressure testing machine, the power supply voltage must be accurate; Darmstadt Merck, a leading enterprise providing innovative and high-quality high-tech products in the fields of medicine and health, life sciences and high-performance materials, announced that it had successfully completed the year's important strategic projects and achieved the year's goals

the chairman of Merck's executive board, Peter klovi, said in Darmstadt, Germany on Tuesday: "We have strengthened Merck's three business areas: medical health, life sciences and high-performance materials. The successful acquisition of AZ electronic materials, the launch of the acquisition of sigma Aldrich and the alliance with Pfizer in the field of immunooncology have laid the foundation for our future growth. These achievements are what we have achieved through the implementation of the long-term transformation and growth strategy. Merck is transforming into a highly specialized enterprise The goal of a ball technology enterprise is to improve the lives of patients and customers. "

block this promotion content

Merck group's total revenue increased by 3.7% in 2014, reaching 11.5 billion euros (2013: 11.1 billion euros). Sales increased by 5.5% to 11.3 billion euros (2013: 10.7 billion euros). This is mainly due to the organic growth of 4.0% and the acquisition growth of 3.3%, of which the successful acquisition of AZ electronic materials company is indispensable. At the same time, however, sales fell by 1.8% due to adverse exchange rate fluctuations

the shell of Merck's nose is bolted to the fuselage. Its operating performance (EBIT: EBIT) increased significantly by 9.4% to 1.8 billion euros (2013: 1.6 billion euros). The key financial indicator guiding the business operation, ebitdapreone timeitems, climbed 4.1% to 3.4 billion euros (2013: 3.3 billion euros), which also benefited from good operating performance and the successful acquisition of AZ electronic materials. The steady growth and good development of operating business also significantly offset the sharply reduced royalties, royalties and commission income, which decreased by 47% compared with last year to 209 million euros (2013:395 million euros). Net income, that is, the after tax profit attributable to Merck shareholders, was 1.157 billion euros in 2014 (2013: 1.202 billion euros), a decrease of 3.7%, because Merck benefited from a one-time extremely low tax rate of 13% in 2013

considering that the company split its shares at a ratio of 1:2 in June 2014, the earnings per share of Merck group under the one-time project increased by 4.8% to 4.60 euros per share (2013:4.39 euros). Therefore, Merck will propose to increase the dividend of € 0.05 to € 1.00 per share at the annual general meeting of shareholders

even though it raised about 1.9 billion euros for the acquisition of AZ electronic materials, the net financial liabilities of Merck group increased by only 252 million euros to 559 million euros (2013:307 million euros). On June 30, 2014, net financial debt briefly rose to 2.2 billion euros. This proves once again the strong ability of Merck group to conduct internal financing, and also shows that Merck is fully prepared to acquire sigma Aldrich. As of December 31, 2014, Merck had 39639 employees around the world (2013: 38154 employees) with good friction properties of nylon materials made from short fibers bonded together

therefore, Merck can achieve the predicted moderate growth in sales, EBITDA before one-time projects and earnings per share before one-time projects. The cash flow of the enterprise is expected to increase slightly, but the result does not meet the expected goal

fourth quarter of 2014: Sales and EBITDA before one-time projects increased significantly

in the fourth quarter of 2014, Merck increased strongly compared with the same period last year, with an increase of 12.9%, to 3billion euros (fourth quarter of 2013: 2.6 billion euros). In addition to the organic growth of 4.4%, Merck can achieve significant growth under the combined effect of the acquisition of AZ electronic materials and favorable foreign exchange conditions. Therefore, despite declining royalties, royalties and commission income, EBITDA before one-time projects increased by 10.5% to 878million euros (fourth quarter of 2013: 795million euros). EBITDA earnings per share before one-time projects rose 7.5% to 1.14 euros per share (fourth quarter 2013: 1.06 euros per share)

the booming business in emerging markets has become the driving force for the organic growth of Merck xuelanuo

Merck biopharmaceutical business branch Merck xuelanuo's organic sales growth hit a record high of 3.6% in 2014. Despite the negative growth of 1.9% due to unfavorable foreign exchange factors, its overall sales increased by 1.7% to 5.8 billion euros. Merck Serono's business units in all treatment fields have driven the growth of the company's performance, of which the net increase in sales is mainly from the reproductive business unit. From a geographical perspective, emerging market regions have the strongest growth

the drug benefit ratio for the treatment of recurrent multiple sclerosis disease, despite the increasing competitive pressure caused by oral preparations, its organic sales in 2014 decreased only slightly by 0.2%. Although 1.2% was dragged down by the adverse fluctuation of the exchange rate, the Libby sales still reached 1.8 billion euros. In 2014, the sales of tumor drug ibital organically increased by 5.9%. The overall sales of ibital increased by 22million euros to 904million euros, including -3.4% dragged down by adverse foreign exchange factors. Despite the impact of adverse exchange rates, the organic sales of gounafen, a leading recombinant hormone drug in the field of infertility treatment, increased by 9.1% in 2014. The sales volume of guonafen rose to 628million euros

in 2014, Merck snow increased its R & D investment and continued to focus on strategic and important R & D product lines and the termination of individual research projects with small development prospects. At the same time, in 2014, Merck Snow's royalties, royalties and commission revenue fell sharply by 48.5% to 192 million euros (2013: 372 million euros). Other operating expenses and income (net) have improved significantly. This resulted in a 1.3% decline in EBITDA before one-time projects, totalling € 1.8 billion (2013: € 1.9 billion)

Ke Luwei said: "in 2014, the performance of our listed drugs increased strongly. In addition, through the alliance with Pfizer in the field of immune oncology, we set an important milestone in our efforts to further develop the pharmaceutical R & D product line. Ke Luwei added:" this will help us fully develop the potential of anti-PD-L1 antibody avelumab "

consumer health business: the core business grew steadily

in 2014, Sales of the consumer health business of the over-the-counter drugs business increased by 3.2% to 766million euros (2013:742million euros). The organic growth of sales volume reached 5.4%, but the adverse factors of foreign exchange dragged down 2.2%. On the one hand, Europe and emerging markets are the main driving forces for the organic growth and overall good development of the sector; The three strategic brands (neurobion, Femibion and floritil) and German local brands have also achieved good organic growth. In order to consolidate the market position of strategic brands, the consumer health department has increased its investment in marketing and sales, but its EBITDA before one-time projects is still 169million euros (2013: 172 million euros), basically the same as the profitability of 2013

Ke Luwei said, "consumer health focuses its OTC drug business on core brands and core markets, which is the right way to further increase its performance in 2014. Since the beginning of 2015, consumer health business has been part of the medical health business."

the sales of high-performance materials soared thanks to the acquisition of AZ electronic materials and organic growth

Merck group's special chemical business - high-performance materials business (raw functional materials business), whose sales increased by 25.4% in 2014 to 2.1 billion euros (2013: 1.6 billion euros). The steady organic growth of 4.1% and the new sales after the acquisition reached 22.8%, equivalent to 375million euros, which made the sales of high-performance materials rise sharply. Among them, the unfavorable factors of foreign exchange dragged down 1.5% of sales. All existing business departments have achieved organic growth, and the LCD business department has made the greatest contribution to the growth of sales. Merck's LCD business unit is a global market and innovation leader, which also benefits from the changing demand of the LCD market - the strong demand for high-tech complex LCD used in large high-quality TV screens, such as ultra-high definition devices. This growth has also driven the development of energy-saving ub-ffs (ultra bright edge field switch) technology and promoted its sales growth. This technology is widely used in the new generation of smart and tablet computer displays. The pigment and cosmetics business department achieved small organic growth in sales. Xirallic pigment products (mainly used for high-quality automotive coatings) and technical functional materials are the main driving forces for organic growth. Due to the high demand for organic light emitting diode (OLED) displays, the advanced technology business department has made a great contribution to the organic growth of high-performance materials

in 2014, EBITDA before one-time projects of high-performance materials increased by 14.8% to 895million euros (2013: 780million euros), which is particularly due to the successful acquisition of AZ electronic materials

Ke Luwei, CEO of Merck group, explained: "Merck group not only benefits from the general trend of digitalization, but also actively participates in shaping the digitalization trend, such as the development of energy-saving and power-saving display materials. The mature and innovative products of the liquid crystal business department have achieved good performance, and we are particularly pleased to see the growth of Merck group's sales after the acquisition of AZ electronic materials. At the same time, AZ electronic materials has fully integrated into us, and also optimized and improved our business Combination. "

Merck millipore's business benefited from the strong demand in the field of biotechnology

Merck millipore is the life science business of Merck group, and its organic sales increased steadily by 4.5% in 2014. The good sales performance of the process solutions business department contributed to the growth rate. From the perspective of business regions, sales in emerging markets are showing a positive development trend. Although affected by the adverse factors of foreign exchange and the divestment of the discovery and development solutions business unit, the overall sales increased by 2.1% to 2.7 billion euros (2013: 2.6 billion euros). The pre project EBITDA of Merck millipore increased by 2.5% to 659 million euros (2013: 643 million euros)

the business of the process solutions business department is to sell products used in the pharmaceutical production field, and its organic sales increased strongly, reaching 8.9%. This is mainly due to the increasing demand for consumables and purification solutions in the biopharmaceutical industry. The laboratory solutions business department provided a wide range of products for researchers and scientific laboratories, achieving an organic sales growth of 1.9%. The business of Bioscience business department is to sell products and services to pharmaceutical and academic research laboratories, and its organic sales decreased slightly by 0.5%. In addition, lower antibody demand also frustrates sales

Ke Luwei said, "we provide patients, customers and society with solutions to achieve growth. We

Copyright © 2011 JIN SHI